BioMarker Strategies is a Maryland-based company that has developed the SnapPath Cancer Diagnostics System, a proprietary and patented technology for predictive tests in targeted drug development and treatment selection for patients with solid tumor malignancies. Their mission is to advance personalized medicine by automating and standardizing functional ex vivo profiling of live solid tumor cells, resulting in highly predictive biomarker tests for individual response to targeted treatments.
With a focus on entering funded collaborations with companies developing targeted therapies for solid tumors, BioMarker Strategies offers the capabilities of SnapPath and its PathMAP Functional Signaling Profiles for research use in preclinical and early clinical studies. The company has been recognized for its innovative technologies through various patents and grants, positioning them as a leading player in the field of personalized cancer diagnostics.
Generated from the website